结直肠癌肺转移灶切除与继续主动监测的随机对照试验(PulMiCC)
PulMiCC是一项多中心随机对照试验,纳入65例可切除肺转移的结直肠癌患者,比较主动监测联合或不联合转移灶切除。5年死亡风险比0.82(95%CI 0.43,1.56)。因招募困难提前终止,转移灶切除组估计生存38%,匹配对照组29%,挑战了既往认为绝对生存获益约35%的观念。
要点
- 转移灶切除组5年生存估计38%,对照组29%,差异无统计学显著性。
- 5年死亡风险比0.82(95%CI 0.43,1.56),置信区间宽,不能排除获益或无效。
- 研究因招募缓慢提前终止,样本量小(N=65),无法得出确切结论。
核心结论
- 因招募困难提前终止,小样本(N=65)无法对肺转移灶切除的生存获益给出确切结论。
- 转移灶切除组估计5年生存38%(23-62%),匹配对照组29%(16-52%),与既往认为的绝对获益约35%不符。
研究设计与样本
- 多中心、两臂随机对照试验,13家医院参与,比较主动监测联合或不联合肺转移灶切除。
- 共随机65例参与者,随机化远程进行,按中心分层,并对年龄、性别、原发癌分期等因素进行最小化平衡。
- 分析为意向性治疗,非劣效界值为10%。
主要发现
- 5年死亡风险比(转移灶切除 vs 对照)为0.82(95%CI 0.43,1.56)。
- 前6个月无其他干预,无对照组交叉至治疗组,无治疗相关死亡或重大不良事件。
- 转移灶切除组估计生存38%(23-62%),对照组29%(16-52%)。
临床怎么用
- 现有证据不足以支持将肺转移灶切除作为结直肠癌肺转移的常规标准治疗。
- 临床决策应个体化,并充分告知患者生存获益的不确定性。
局限性
- 样本量小(N=65),置信区间宽,统计效能不足。
- 因招募缓慢提前终止,结果可能受选择偏倚影响。
- 随访时间及事件数有限,长期生存差异无法可靠评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lung metastasectomy in the treatment of advanced colorectal cancer has been widely adopted without good evidence of survival or palliative benefit. We aimed to test its effectiveness in a randomised controlled trial (RCT). METHODS: Multidisciplinary teams in 13 hospitals recruited participants with potentially resectable lung metastases to a multicentre, two-arm RCT comparing active monitoring with or without metastasectomy. Other local or systemic treatments were decided by the local team. Randomisation was remote and stratified by site with minimisation for age, sex, primary cancer stage, interval since primary resection, prior liver involvement, the number of metastases, and carcinoembryonic antigen level. The central Trial Management Group were blind to patient allocation until completion of the analysis. Analysis was on intention to treat with a margin for non-inferiority of 10%. RESULTS: Between December 2010 and December 2016, 65 participants were randomised. Characteristics were well-matched in the two arms and similar to those in reported studies: age 35 to 86 years (interquartile range (IQR) 60 to 74); primary resection IQR 16 to 35 months previously; stage at resection T1, 2 or 3 in 3, 8 and 46; N1 or N2 in 31 and 26; unknown in 8. Lung metastases 1 to 5 (median 2); 16/65 had previous liver metastases; carcinoembryonic antigen normal in 55/65. There were no other interventions in the first 6 months, no crossovers from control to treatment, and no treatment-related deaths or major adverse events. The Hazard ratio for death within 5 years, comparing metastasectomy with control, was 0.82 (95%CI 0.43, 1.56). CONCLUSIONS: Because of poor and worsening recruitment, the study was stopped. The small number of participants in the trial (N = 65) precludes a conclusive answer to the research question given the large overlap in the confidence intervals in the proportions still alive at all time points. A widely held belief is that the 5-year absolute survival benefit with metastasectomy is about 35%: 40% after metastasectomy compared to < 5% in controls. The estimated survival in this study was 38% (23-62%) for metastasectomy patients and 29% (16-52%) in the well-matched controls. That is the new and important finding of this RCT. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT01106261. Registered on 19 April 2010.
引用
- Treasure T, Farewell V, Macbeth F, et al. Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial. Trials. 2019. PMID: 31831062. doi:10.1186/s13063-019-3837-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。